These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 14726653)

  • 21. Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest.
    Han C; Leng J; Demetris AJ; Wu T
    Cancer Res; 2004 Feb; 64(4):1369-76. PubMed ID: 14973068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kinetic basis for selective inhibition of cyclo-oxygenases.
    Gierse JK; Koboldt CM; Walker MC; Seibert K; Isakson PC
    Biochem J; 1999 May; 339 ( Pt 3)(Pt 3):607-14. PubMed ID: 10215599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Involvement of cyclooxygenase-derived prostaglandin E2 and nitric oxide in the protection of rat pancreas afforded by low dose of lipopolysaccharide.
    Jaworek J; Bonior J; Tomaszewska R; Jachimczak B; Kot M; Bielański W; Pawlik WW; Sendur R; Stachura J; Konturek PC; Konturek SJ
    J Physiol Pharmacol; 2001 Mar; 52(1):107-26. PubMed ID: 11321505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Specific inhibitors of cyclooxygenase-2 (COX-2): current knowledge and perspectives].
    Rioda WT; Nervetti A
    Acta Biomed Ateneo Parmense; 2001; 72(3-4):55-64. PubMed ID: 11889908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclooxygenase-1 vs. cyclooxygenase-2 inhibitors in the induction of antinociception in rodent withdrawal reflexes.
    Mazario J; Gaitan G; Herrero JF
    Neuropharmacology; 2001 Jun; 40(7):937-46. PubMed ID: 11378164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design and synthesis of celecoxib and rofecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of sulfonamide and methylsulfonyl pharmacophores by an azido bioisostere.
    Habeeb AG; Praveen Rao PN; Knaus EE
    J Med Chem; 2001 Aug; 44(18):3039-42. PubMed ID: 11520213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COX-2 inhibitors: the next generation of non-steroidal anti-inflammatory drugs.
    Schachna L; Ryan PF
    Med J Aust; 1999 Aug; 171(4):175-6. PubMed ID: 10494231
    [No Abstract]   [Full Text] [Related]  

  • 28. COX-2 specific inhibitors offer improved advantages over traditional NSAIDs.
    Urban MK
    Orthopedics; 2000 Jul; 23(7 Suppl):S761-4. PubMed ID: 10914695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis.
    Goldenberg MM
    Clin Ther; 1999 Sep; 21(9):1497-513; discussion 1427-8. PubMed ID: 10509845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Up-regulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: a key to nonsteroidal anti-inflammatory drug-induced intestinal damage.
    Tanaka A; Hase S; Miyazawa T; Takeuchi K
    J Pharmacol Exp Ther; 2002 Mar; 300(3):754-61. PubMed ID: 11861778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Different cell kinetic changes in rat stomach cancer after treatment with celecoxib or indomethacin: implications on chemoprevention.
    Yu J; Tang BD; Leung WK; To KF; Bai AH; Zeng ZR; Ma PK; Go MY; Hu PJ; Sung JJ
    World J Gastroenterol; 2005 Jan; 11(1):41-5. PubMed ID: 15609394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells.
    Lev-Ari S; Strier L; Kazanov D; Madar-Shapiro L; Dvory-Sobol H; Pinchuk I; Marian B; Lichtenberg D; Arber N
    Clin Cancer Res; 2005 Sep; 11(18):6738-44. PubMed ID: 16166455
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis.
    Fischer SM; Lo HH; Gordon GB; Seibert K; Kelloff G; Lubet RA; Conti CJ
    Mol Carcinog; 1999 Aug; 25(4):231-40. PubMed ID: 10449029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex).
    Wynn RL
    Gen Dent; 2000; 48(1):16-20. PubMed ID: 11199547
    [No Abstract]   [Full Text] [Related]  

  • 36. [Therapy with preferential and specific COX-2 inhibitors].
    Stichtenoth DO; Frölich JC
    Internist (Berl); 2001 Mar; 42(3):421-6. PubMed ID: 11277028
    [No Abstract]   [Full Text] [Related]  

  • 37. Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts.
    Raut CP; Nawrocki S; Lashinger LM; Davis DW; Khanbolooki S; Xiong H; Ellis LM; McConkey DJ
    Cancer Biol Ther; 2004 Dec; 3(12):1217-24. PubMed ID: 15477758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors.
    Richter M; Weiss M; Weinberger I; Fürstenberger G; Marian B
    Carcinogenesis; 2001 Jan; 22(1):17-25. PubMed ID: 11159736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis.
    Erickson BA; Longo WE; Panesar N; Mazuski JE; Kaminski DL
    J Surg Res; 1999 Jan; 81(1):101-7. PubMed ID: 9889067
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanism of inhibition of novel COX-2 inhibitors.
    Gierse J; Kurumbail R; Walker M; Hood B; Monahan J; Pawlitz J; Stegeman R; Stevens A; Kiefer J; Koboldt C; Moreland K; Rowlinson S; Marnett L; Pierce J; Carter J; Talley J; Isakson P; Seibert K
    Adv Exp Med Biol; 2002; 507():365-9. PubMed ID: 12664611
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.